SMAD2 and obesity disorder: Signaling impairments in sarcopenic obesity include marked AMPK/PGC-1α suppression, chronic NF-κB/JNK and SMAD2/3 activation, and disrupted autophagy–mitophagy cycles—alterations that synergistically promote IR and metabolic inflexibility [78].